These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32114448)

  • 41. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and inhibitory activity of thymidine analogues targeting Mycobacterium tuberculosis thymidine monophosphate kinase.
    Van Poecke S; Munier-Lehmann H; Helynck O; Froeyen M; Van Calenbergh S
    Bioorg Med Chem; 2011 Dec; 19(24):7603-11. PubMed ID: 22061826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis.
    Aguilar-Pérez C; Gracia B; Rodrigues L; Vitoria A; Cebrián R; Deboosère N; Song OR; Brodin P; Maqueda M; Aínsa JA
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans.
    Pochet S; Dugué L; Labesse G; Delepierre M; Munier-Lehmann H
    Chembiochem; 2003 Aug; 4(8):742-7. PubMed ID: 12898625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prospects for design of novel antituberculosis drugs].
    Nikitin AV
    Antibiot Khimioter; 2006; 51(9-10):56-60. PubMed ID: 18030793
    [No Abstract]   [Full Text] [Related]  

  • 46. Advances in Computational Studies of Potential Drug Targets in Mycobacterium tuberculosis.
    Alladi SM
    Curr Top Med Chem; 2018; 18(13):1062-1074. PubMed ID: 30084331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antituberculosis drugs: ten years of research.
    Janin YL
    Bioorg Med Chem; 2007 Apr; 15(7):2479-513. PubMed ID: 17291770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tuberculosis. The WHO/IUATLD Global Project on Antituberculosis Drug-Resistance Surveillance.
    Wkly Epidemiol Rec; 1996 Sep; 71(38):281-5. PubMed ID: 8870501
    [No Abstract]   [Full Text] [Related]  

  • 49. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
    Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium tuberculosis.
    Barbosa AR; Caleffi-Ferracioli KR; Leite CQ; García-Ramos JC; Toledano-Magaña Y; Ruiz-Azuara L; Siqueira VL; Pavan FR; Cardoso RF
    Chemotherapy; 2016; 61(5):249-55. PubMed ID: 26950478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics.
    Machado D; Azzali E; Couto I; Costantino G; Pieroni M; Viveiros M
    Future Microbiol; 2018 Sep; 13():1383-1402. PubMed ID: 30259757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing.
    Zignol M; van Gemert W; Falzon D; Jaramillo E; Blanc L; Raviglione M
    Clin Infect Dis; 2011 Apr; 52(7):901-6. PubMed ID: 21427397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Research progresses of Mycobacterium tuberculosis cytochrome P450s as a potential drug target].
    Lu Y; Qiao F; You XF; Yang XY
    Yao Xue Xue Bao; 2014 Apr; 49(4):427-34. PubMed ID: 24974457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rational design of coumarin derivatives as antituberculosis agents.
    Mali HM; Sabale SS; Degani MS; Borkute R; Choudhari AS; Sarkar D; Krishna VS; Sriram D
    Future Med Chem; 2018 Oct; 10(20):2431-2444. PubMed ID: 30325198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting tuberculosis: a glimpse of promising drug targets.
    Arora N; Banerjee AK
    Mini Rev Med Chem; 2012 Mar; 12(3):187-201. PubMed ID: 22356190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of new anti-tuberculosis drug candidates.
    Shi R; Sugawara I
    Tohoku J Exp Med; 2010 Jun; 221(2):97-106. PubMed ID: 20467231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluoroquinolones, tuberculosis, and resistance.
    Ginsburg AS; Grosset JH; Bishai WR
    Lancet Infect Dis; 2003 Jul; 3(7):432-42. PubMed ID: 12837348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review on various heterocyclic moieties and their antitubercular activity.
    Sharma S; Sharma PK; Kumar N; Dudhe R
    Biomed Pharmacother; 2011 Jul; 65(4):244-51. PubMed ID: 21715130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.